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Background: Almost 30% of children in Southern Africa are HIV exposed but uninfected 
(HEU) and experience exposures that could increase vulnerability to infectious diseases 
compared to HIV unexposed (HU) children. The mechanisms of HEU infant vulnerability 
remain ill-defined. This review seeks to appraise the existing clinical evidence of the pat-
tern of HEU infant infectious morbidity to aid understanding of the potential mechanism 
of susceptibility.
Methods: A systematic search was conducted of scientific literature databases and 
conference proceedings up to December 2015 for studies comparing adequately defined 
HEU (in whom HIV-infection had been excluded through age-appropriate testing) and HU 
infants for all-cause mortality, all-cause hospitalization, or an infection-related morbidity. 
The systematic review was complemented by a narrative review of additional studies 
detailing the pattern of infectious morbidity experienced by HEU children without com-
parison to HU children or without conclusive exclusion of HIV-infection in HIV-exposed 
infants.
Results: Only 3 of 22 eligible identified studies were designed to primarily compare HEU 
and HU infants for infectious morbidity. Fourteen were conducted prior to 2009 in the 
context of limited antiretroviral interventions. Three patterns emerge: (1) causes of mor-
bidity and mortality in HEU infants are consistent with the common causes of childhood 
morbidity and mortality (pneumonia, diarrheal disease, and bacterial sepsis) but occur 
with greater severity in HEU infants resulting in higher mortality, more frequent hospital-
ization, and more severe manifestations of disease; (2) the greatest relative difference 
between HEU and HU infants in morbidity and mortality occurs beyond the neonatal 
period, during mid-infancy, having waned by the second year of life; and (3) HEU infants 
are at greater risk than HU infants for invasive streptococcal infections specifically Group 
B Streptococcus and Streptococcus pneumonia.
TABLe 1 | Search term strategy.
Search terms
1. HIV infect* OR HIV OR HIV-1 OR HIV-2 OR HIV1 OR HIV2 OR human 
immune*
2. Infant OR child OR infan* OR childr* OR paediatric OR pediatric
3. Mortality OR morbidity OR infectio* OR diarrhoea OR diarrhea OR diarrh* 
OR pneumonia* OR pneumo* OR respiratory OR sepsis OR septic* OR 
bacteria* OR virus OR viral
4. HIV exposed uninfected OR HEU OR HIV-EU OR HIV unexposed OR HUU 
OR HU OR HIV-UE OR HIV-uninfected
5. 1 AND 2 AND 3 AND 4
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inTRODUCTiOn
Globally, approximately 1.4 million HIV-infected women become 
pregnant annually (1). Expanding vertical HIV transmission pre-
vention (VTP) programs have markedly reduced HIV transmis-
sion, but for those HIV-exposed but uninfected (HEU) children, 
there are consequences of being born to an HIV-infected mother 
(1). HEU infants experience numerous exposures during fetal 
and early life that could increase their vulnerability to infectious 
diseases during infancy compared to HIV unexposed (HU) 
infants. Risk factors for HEU infant infectious morbidity and 
mortality can be divided into two groups: (1) Universal infant 
risk factors. These include prematurity or small for gestational 
age, absence of or suboptimal breastfeeding, maternal mortality, 
exposure to infectious agents particularly tuberculosis (TB), and 
poverty (2–11); (2) risk factors unique to HIV-exposed infants. 
These include exposure to the in utero environment altered by 
HIV, including exposure to viral proteins and glycoproteins, 
a pro-inflammatory state in the mother, maternal immune 
compromise, exposure to antiretroviral (ARV) and other drugs 
in  utero and in breast milk (12–18). Understanding whether 
HIV-exposure plays a direct role in HEU infant risk for morbidity 
and mortality requires consideration of the universal infant risk 
factors as confounders to the relationship between HIV-exposure 
and infectious morbidity.
A number of perturbations of the HEU infant immune 
system, most likely as a result of HEU-unique exposures, have 
been observed (19). However, these immune system changes have 
not yet been studied in direct association with risk for infectious 
morbidity, probably the consequence of greatest importance 
for the majority of HEU infants and children living in regions 
experiencing high infectious disease-related child mortality (15, 
20–26). Interrogation of the clinical pattern of infectious mor-
bidity in HEU children could aid understanding of the potential 
mechanism of susceptibility and define a focus for further immu-
nologic investigations within the vastness of the infant immune 
system. To this end, this review seeks to better understand the 
existing evidence of HEU infant vulnerability for infectious 
disease morbidity. Detailed reviews on HEU infant innate and 
humoral immunity are included in this special issue and will not 
be considered here.
MeTHOD
This paper comprises a systematic review of the literature for 
studies comparing infectious morbidity in HEU and HU infants 
and children, as well as a narrative review of two additional types 
of studies, the first detailing the pattern of infectious morbidity 
experienced by HEU infants and children without comparison 
to HU children, and the second, without conclusive exclusion of 
HIV infection in HIV-exposed infants. For the systematic review, 
the literature was searched for studies comparing adequately 
defined HEU (in whom HIV-infection had been excluded 
through age-appropriate serologic or virologic testing) and HU 
infants for all-cause mortality, all-cause hospitalization, or an 
infection-related morbidity. Databases searched up to December 
2015 included Medline, Embase, Cochrane Central Register of 
Controlled Trials, Cochrane Database of Systematic Reviews, 
and the following conference proceedings: International AIDS 
Society Conference on HIV Pathogenesis, Treatment and 
Prevention; International AIDS Conference; Conference of 
Retroviruses and Opportunistic Infections. Reference lists of 
identified manuscripts were scrutinized for additional studies. 
The search term strategy is detailed in Table 1. The systematic 
search identified 498 studies. Following title review, the abstracts 
of 149 studies and full-text of 32 studies were reviewed. Twenty-
two eligible studies are summarized, and their evidence is 
discussed.
Review
Most of what is known about HEU infant infectious morbidity 
comes from observations made early in the epidemic describ-
ing the natural history of HIV infected children compared to 
HIV-uninfected children, both HIV exposed and unexposed, 
or from secondary analyses of VTP clinical trials often without 
an HU control group (16, 27–32). Twenty-two studies com-
paring adequately defined HEU to HU infants for all-cause 
mortality, all-cause hospitalization, or infectious morbidity were 
identified, 21 from sub-Saharan Africa and 1 from Denmark 
Conclusion: To definitively understand HEU infant infectious morbidity risk, substantially 
larger prospective studies with appropriate HU infant comparison groups are necessary. 
HEU children would benefit from collaboration among researchers to achieve the quality 
of evidence required to improve HEU infant outcomes globally. HEU infant health and 
well-being, beyond avoiding HIV-infection, deserves a more prominent position in the 
local and international HIV research agendas.
Keywords: Hiv exposed uninfected, HeU, infection, review, infant
TABLe 2 | Studies comparing mortality and infectious morbidity in Hiv-exposed uninfected and Hiv-unexposed children in sub-Saharan Africa.
Reference Country  
(year)
Study type; sample size 
(HeU:HU)
Outcome Follow-up Findings [HeU vs. HU; point estimate 
(95% Ci)]
All-cause mortality and hospitalization
1. Spira et al. (28) Rwanda 
(1989–1994)
Prospective cohort; 
(138:209)
Natural history of HIV 
in children
0–60 months Severe pneumonia aHR 1.4 (0.9, 2.0); 
hospitalization aHR 1.3 (0.9, 1.4)
2. Taha et al. (29) Malawi 
(1994–1997)
VTP RCT (499:119) Morbidity 6–36 months No difference in numerous morbidities
3. Brahmbhatt et al. (17) Uganda 
(1994–1998)
Community surveillance 
(269:3183)
All-cause mortality 0–24 months Mortality 18 months aIRR 1.16 (p < 0.05)
4. Marinda et al. (33);  
 Koyanagi et al. (34)
Zimbabwe 
(1997–2000)
VTP RCT (3135:9210) All-cause hospitalization 
and mortality
0–24 months Mortality: 2–6 months aIRR 5.5 (3.9, 7.9); 
throughout 24 months aIRR >2 (1.2, 7.9); 
hospitalization: neonatal aIRR 1.5 (1.2, 2.0); 
post-neonatal aIRR 1.2 (0.9, 1.6)
5. Shapiro et al. (35) Botswana 
(2000–2005)
VTP RCT (534:137) All-cause hospitalization 
and mortality
0–24 months Mortality aRR 4.2 (p < 0.01); Hospitalization aRR 
2.17 (p < 0.001)
6. Homsy et al. (36) Uganda 
(2007–2008)
Prolonged co-trimoxazole 
RCT (185:100)
Adverse event and 
hospital admissions
0–48 months No difference in incidence of hospitalization or 
grade 3/4 adverse events
7. Landes et al. (37) Malawi 
(2008–2009)
Retrospective VTP program 
evaluation (128:200)
All-cause hospitalization 0–20 months No difference in hospitalization
8. Moraleda et al. (38) Mozambique 
(2008–2009)
Prospective cohort 
(Total 153)
Sick clinic visits and 
hospitalization
0–12 months Sick clinic visit: uIRR 0.79 (0.63, 0.99); 
Hospitalization: uIRR 1.51 (0.71, 3.18)
9. Slogrove et al. (39) South Africa 
(2009–2011)
Prospective cohort (27:28) Infectious cause 
hospitalization 
0–12 months Sick clinic visit: uIRR 1.06 (0.79, 1.39); 
hospitalization: uIRR 2.74 (0.75, 8.78)
10. Marquez et al. (40) Uganda 
(2010–2013)
Malaria prevention RCT 
(186:389)
Morbidity and all-cause 
mortality
6–24 months No difference breastfed HEU and breastfed HU 
6–11 months old
11. Slogrovec (41) South Africa 
(2012–2014)
Birth cohort (94:82) Infectious cause 
hospitalization 
0–6 months Sick clinic visit: uIRR 0.82 (0.58, 1.16); all 
hospitalization: aOR 1.45 (0.4, 4.5); very severe 
hospitalization: aOR 4.2 (1.0, 19.2)
Diarrhea-specific morbidity
12. Thea et al. (27) DRC (Zaire) 
(1989–1992)
Prospective cohort 
(139:191)
Diarrhea incidence 0–12 months Persistent diarrhea incidence 4.9 vs. 2.7/100 py 
(p = 0.23)
13. Rollins et al. (42) South Africa 
(2001–2005)
Breastfeeding intervention 
cohort (936:115)
Diarrheal morbidity and 
all-cause mortality
0–18 months Diarrhea at 6 months aHR 1.45 (0.75, 2.79); 
mortality 12 months aHR 0.77 (0.49, 1.21);
14. Pavlinac et al. (43) Kenya 
(2011–2013)
Cross-sectional diarrhea 
surveillance (105:821)
Enteric pathogen 
prevalence
6–180b months Cryptosporidum spp. aPR 2.7 (1.3–5.6)
Pneumonia-specific morbidity
15. Izadnegahdar  
  et al. (44)
South Africa 
(1999–2001)
Severe pneumonia RCT 
(40:244)
Severe pneumonia 
treatment failure
3–59b months uOR 2.19 (0.75–2.75)
16. McNally et al. (45) South Africa 
(2001–2002)
Hospital cohort (41:75) Severe pneumonia 
treatment failure
0–12b months aOR 6.02 (1.55, 23.38)
17. Kelly et al.c (46) Botswana 
(2012–2013)
Prospective hospital cohort 
(64:153)
Severe pneumonia 
treatment failure
1–23b months Treatment failure: aRR1.83 (1.27, 2.64); Mortality 
aRR 4.31 (1.44, 12.87)
18. Le Roux et al. (47) South Africa 
(2012–2014)
Birth cohort (130:567) Pneumonia incidence 0–12 months All pneumonia: aIRR 1.62 (1.0, 2.6); severe 
pneumonia: uIRR 4.04 (1.5, 10.8)
Other specific morbidity
19. Cutland et al. (48) South Africa 
(2004–2007)
RCT (1255:5804) Neonatal sepsis 
incidence
0–1 month Propensity score matched analysis: early onset 
(20.6 vs. 33.7/1000 live births); late onset (5.8 
vs. 4.1 per 1000 live births)
20. Madhi et al. (49) South Africa 
(2009–2010)
Cross-sectional acute otitis 
surveillance (63:182)
Otopathogen 
prevalence
3–59b months No difference in type of otopathogens 
21. Von Mollendorf  
   et al.c (50)
South Africa 
(2009–2013)
Laboratory surveillance 
(253 HEU cases:377 HU 
cases)
IPD incidencea and 
mortality
0–12b months IPD aRR 0–6 months 3.6 (2.8, 4.6); mortality 
due to IPD aOR 1.76 (1.09, 2.85)
aCalculated using a population-based denominator.
bAge at time of event.
cDesigned to primarily compare HEU and HU infants for an infection-related morbidity.
DRC, Democratic Republic of Congo; HEU, HIV exposed uninfected; HR, hazard ratio; HU, HIV unexposed; IPD, invasive pneumococcal disease; IRR, incidence rate ratio; OR, odds 
ratio; PR, prevalence ratio; RCT, randomized controlled trial; RR, risk ratio; VTP, vertical transmission prevention; prefix “a,” adjusted; prefix “u,” unadjusted.
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(17,  27–29,  33–51). Among the 21 African studies, 14 were 
conducted prior to 2009 in the context of limited ARV inter-
ventions for either maternal health or VTP. Only three studies 
were designed to primarily compare these two groups of infants 
(Table 2 studies 11, 17, and 21) (41, 46, 50). A major limitation 
of these studies is either due to study design or measurement 
limitations, they have not consistently considered confounding 
by universal infant risk factors of infectious morbidity and mor-
tality; therefore, the role of direct HIV-exposure on infectious 
disease susceptibility is unclear.
All-Cause Mortality and Hospitalization
Studies conducted early in the epidemic did not observe signifi-
cant differences in mortality, hospitalization, or infectious mor-
bidities between HEU and HU children (28, 29). The first study 
to definitively demonstrate a higher mortality and morbidity in 
HEU compared to HU infants was the Zimbabwe Vitamin A for 
Mothers and Babies Project (ZVITAMBO) (Table  2 study 4), 
detailed further in this issue (33, 34). This large cohort study was 
conducted prior to the availability of either ARVs for treatment 
or prevention of HIV transmission or cotrimoxazole chemopro-
phylaxis, and 94% of infants breastfed until 12 months of age. The 
study demonstrated an almost four times greater risk of mortality 
[incidence rate ratio (IRR) 3.9, 95% CI 3.2–4.8] at 12 months and 
two times greater risk of mortality (IRR 2.0, 95% CI 1.2–3.5) at 
24 months in HEU compared to HU infants (33). Similar to HU 
infants, the highest absolute mortality for HEU infants was in 
the neonatal period. The relative increase in HEU mortality was 
greatest between 2 and 6  months of life, reaching 5.5 (95% CI 
3.9–7.9) times that of HU infants (33). Eighty percent of HEU 
mortality occurred during the first 6 months of life. Morbidity, 
measured as sick clinic visits and hospitalizations, was also 
greater in HEU than in HU infants (34). Smaller Southern and 
Eastern African studies confirmed the elevated morbidity and 
mortality in HEU infants in this region (17, 35). The Mashi study 
in Botswana (Table 2 study 5) similar to ZVITAMBO observed 
an at least four times greater risk for mortality and double the risk 
for hospitalization at 6 and 24 months (35).
Two Ugandan studies designed primarily to evaluate pro-
longed co-trimoxazole preventive therapy for malaria chemopro-
phylaxis, or improvement of HEU health did not find substantial 
differences in infectious morbidity (Table 2 studies 6 and 10) (36, 
40). A single study outside of sub-Saharan Africa, utilizing the 
Danish national registry compared 260 Danish HEU children to 
1300 matched HU children for risk of hospital admission before 
age 4 years (51). The IRR for all hospitalizations was 3.2 (95% CI 
2.8–3.7), but the difference between HEU and HU infants was 
in non-malignant hematological disease and other non-specific 
symptoms (IRR 3.2, 95% CI 1.5–7.0) rather than infectious dis-
ease hospitalizations (IRR 1.0, 95% CI 0.79–1.37). Three smaller 
Southern African studies, one from Mozambique and two from 
South Africa, showed an increased risk for hospitalization in 
HEU infants compared to HU infants while out-patient sick 
clinic visits remained similar in both groups (Table 2 studies 8, 
9, and 11) (38, 39, 41). Vaccination uptake was similar in both 
HEU and HU infants in the South African studies (39, 41). One 
of the South African studies specifically considered the severity 
of hospitalization events and observed a four times greater prob-
ability of hospitalization for very severe infectious events in HEU 
compared to HU infants with comparable durations of breast-
feeding (41). Inconsistencies in infectious morbidity outcomes 
between the Ugandan, Danish, and Southern African studies may 
reflect regional differences in infectious morbidity risk in HEU 
infants, differences in the age profile of children observed, with 
younger infants observed in South Africa and Mozambique, or 
alternatively, differences in measurement and analysis of infec-
tious morbidity outcomes.
Cohorts in Europe and the Americas have reported rates of 
hospitalization and other morbidities in HEU children without 
comparison to HU control groups. The European Collaborative 
Study followed more than 1600 HEU infants from 1985 to 2002. 
A hospitalization rate of 264/1000 child-years was observed, and 
the probability of hospitalization was not associated with socio-
demographic factors (52). In a cohort of infants born between 
1985 and 2006 in Belgium, the incidence rate of severe infections 
was 16.8/100 HEU infant years (53). In Puerto Rico and the United 
States between 1989 and 2001, 24% (229/955) of HEU children 
were hospitalized in the first 2 years of life with respiratory tract 
infections occurring most frequently (16%) followed by gastroen-
teritis (11%) (54). A prospective study in Latin America and the 
Caribbean of HIV-infected mothers and their infants described 
infectious disease morbidity in 462 HEU infants up to six months 
of age between 2002 and 2004 (55). Hospitalizations occurred at 
least once in 17.5% of infants, the majority (53%) of admissions 
due to lower respiratory tract infections (LRTI). Although these 
studies have provided valuable descriptions of HEU infants, it is 
difficult to interpret these findings in the absence of comparison 
to HU infants.
Despite some inconsistencies, the existing evidence suggests 
that HEU infants experience greater mortality and hospitaliza-
tion than HU infants. The risk ratios (RRs) for hospitalization 
from the most recent South African and Mozambican studies 
are approximately 1.5 times higher in HEU compared to HU 
infants and although imprecise, raise the possibility of a strong 
association between HIV exposure and infectious morbidity (38, 
41). HIV exposure without HIV infection could account for up 
to one-third of infectious cause hospitalizations in HEU infants. 
In South Africa, for example, with an HIV exposure prevalence 
of almost 30% this would translate to 12.5% of infectious cause 
hospitalizations in all HIV-uninfected infants under 6 months of 
age occurring as a consequence of being born to an HIV-infected 
mother. Therefore, in a birth cohort of approximately one million 
in South Africa, an excess 35 000 infant hospitalizations would 
occur annually (41, 56, 57). Even a RR of 1.1 would produce an 
annual excess of 8100 infant hospitalizations in the same South 
African birth cohort, still a considerable number.
Diarrheal Disease
One of the earliest observations of increased infectious morbid-
ity in HEU infants was from a prospective cohort study in the 
Democratic Republic of Congo between 1989 and 1992 (Table 2 
study 12) (27). HEU infants had almost double the incidence 
of persistent diarrhea than HU infants (4.9 vs. 2.7/100 person 
years) and the hazard of persistent diarrhea was increased further 
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in HEU infants of mothers who died [hazard ratio (HR) 10.4, 
p < 0.005]. In a Kenyan study (Table 2 study 14), the prevalence 
of Cryptosporidium species was three times higher in HEU than 
HU children with acute diarrhea (43). The risk of diarrheal 
disease is intricately tied to infant feeding practices, presenting 
challenges in understanding whether diarrhea-related morbidity 
is due entirely to suboptimal breastfeeding in HEU infants or 
whether HIV exposure specific risk factors also play a role. In a 
South African non-randomized intervention cohort designed to 
determine the effect of exclusive breastfeeding on HIV transmis-
sion and to determine effectiveness of peer support on rates of 
exclusive breastfeeding (Table 2 study 13), all infants exclusively 
breastfed in the first 6 months of life presented with fewer diar-
rheal days than mixed or no breastfeeding with no difference 
between HEU and HU infants (42).
Respiratory infections
A number of studies have described the burden of respiratory tract 
infections in HEU infants, but without HU control groups, it has 
not been possible to understand whether these HEU infants are 
experiencing the morbidity expected of all infants in their context 
or something in excess of that (16, 54, 58, 59). In two studies with 
appropriate HU comparison groups, although the most common 
reason for admission of HEU infants was for a LRTI, this rate 
was no different than that in HU infants requiring hospitalization 
for LRTIs (Table 2 studies 5 and 11) (35, 41). In a third study, 
HEU infants had a marginally significantly greater risk than HU 
infants for all pneumonia (hospitalized and out-patient cases) in 
the first year of life. However, they were at substantially higher 
risk for severe pneumonia (Table 2 study 18) (47). Additionally, it 
has been consistently observed in South African and Botswanan 
studies that HEU infants fail empiric pneumonia treatment more 
often than HU infants (Table 2 studies 15–17) (44–46). Although 
HEU infants experience a substantial burden of respiratory tract 
infections as reflected by the incidence of disease, this incidence 
is no different to HU infants in the same settings (35, 47). These 
two groups of infants may differ in the severity of the LRTIs and 
this is an observation that deserves further evaluation.
Bacterial Sepsis
Irrespective of HIV exposure, the risk for bacterial sepsis is 
highest during the neonatal period when the immature neonatal 
immune system is often unable to contain bacterial infections (60, 
61). Considering all-cause neonatal sepsis in a large South African 
neonatal cohort, HEU neonates had a slightly lower rate than HU 
neonates for early onset (0–7 days of life) and similar rate for late 
onset (8–28 days of life) neonatal sepsis (Table 2 study 19) (48). 
This persisted in a second analysis using propensity score match-
ing to deal with differences in potentially confounding variables 
between HIV-infected and HIV-uninfected mothers. Group B 
Streptococcus (GBS) infection though is significantly increased 
in Belgian and South African HIV-exposed neonates (62–64). 
A Belgian retrospective cohort study observed an almost 20 
times (RR 19.7, 95% CI 7.5–51.7) greater risk of confirmed GBS 
infection in HEU infants compared to the population rate for HU 
infants between 2001 and 2008 (62). This increased risk was also 
associated with more severe manifestations of disease including 
septic shock, meningitis, and late-onset disease. In South Africa, 
HIV-exposed infants had a 70% greater risk of early onset GBS 
disease (IRR 1.69, 95% CI 1.28–2.24) and three times increased 
risk of late-onset GBS disease (IRR 3.18, 95% CI 2.34–4.36), 
with replication of these findings in a later study in the same 
population (63, 65).
A South African nationwide invasive pneumococcal disease 
(IPD) laboratory surveillance study showed that during the 
first 6  months of life HEU South African infants have a three 
times greater risk for IPD that includes pneumonia, bacterial 
septicemia, and meningitis when compared to HU infants, and 
almost double the probability of IPD mortality independent of 
infant pneumococcal vaccination (Table  2 study 21) (50). In 
keeping with this, a four times greater risk for IPD was observed 
in Belgian HEU infants, born between 1985 and 2006, compared 
to the general infant population prior to pneumococcal conjugate 
vaccination (53). The risk for all-cause bacterial sepsis has not 
been evaluated in HEU infants directly compared to HU infants 
beyond the neonatal period. The French Perinatal Cohort showed 
an association in HEU infants between serious bacterial infec-
tions and maternal CD4 count near delivery (66). In this study 
of 7638 infants, the adjusted HRs for a serious bacterial infection 
were 1.7 (95% CI 1.2–2.6) and 1.2 (95% CI 0.8–1.9) for infants of 
mothers with CD4 count below 350 cells/μl and 350–500 cells/μl 
respectively, compared to above 500 cells/μl. This suggests that 
severe maternal immune compromise may increase the risk for 
serious bacterial infections in HEU infants.
viral infections
Vertical infection of HEU infants with other viral infections is 
important to consider, most notably due to cytomegalovirus 
(CMV), but also due to Human Herpes Virus 6 (HHV-6) (67, 
68). Direct comparisons of rates of congenital CMV in HEU and 
HU infants have not been published. There is indirect evidence to 
suggest that HEU infants may experience greater risk of congeni-
tal viral infections. HIV-infected mothers more often transmit 
CMV and HHV-6 to their infants than HIV-uninfected mothers 
(68). In both the United States and South Africa, a congenital 
CMV prevalence of approximately 3% has been documented and 
is associated with features of advanced maternal HIV disease, 
high HIV viral load, and CD4 count of below 200 cells/μl (69, 
70). The French Perinatal Cohort has observed a reduction in the 
prevalence of congenital CMV over time as combination ARV 
therapy has expanded, decreasing from 3.5% in 1997–1998 to 
1.2% in 2003–2004 (67).
infectious Morbidity Pattern
From the studies reviewed, three patterns become evident:
 (1) The causes of morbidity and mortality in HEU infants in 
sub-Saharan Africa are no different to the common causes 
of childhood morbidity and mortality in HU infants  –   
pneumonia, diarrheal disease, and bacterial sepsis pre-
dominate. These common childhood infections may occur 
with greater severity in HEU infants resulting in a higher 
mortality, more frequent hospitalization, and more severe 
manifestations of disease (33–35, 38, 41, 45–47, 50);
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 (2) HEU infants are at greater risk than HU infants for invasive 
streptococcal infections specifically GBS and Streptococcus 
pneumoniae (50, 62, 63);
 (3) The neonatal period presents an increased risk for infectious 
morbidity in all infants, irrespective of HIV exposure. The 
greatest relative difference between HEU and HU infants 
occurs beyond the neonatal period, during mid-infancy. 
This is evidenced by the absence of a difference in all-cause 
neonatal sepsis and the relative increase in mortality in HEU 
compared to HU infants peaking between 2 and 6 months of 
age (33, 48).
FUTURe ReSeARCH COnSiDeRATiOnS
To definitively understand HEU infant infectious morbidity risk, 
substantially larger prospective studies with appropriate HU 
infant comparison groups are needed. HEU infants would benefit 
from enhanced collaboration among researchers to achieve the 
quality of evidence required to improve HEU infant outcomes 
globally. Agreement on standardized infectious morbidity out-
come measurement would allow for collaboration of multiple 
cohorts while still pursuing unique individual hypotheses and 
objectives. It is fully recognized that enhanced efforts to improve 
uptake of sustained breastfeeding in HIV-exposed infants are 
required. However, there is evidence that supports that pathways 
other than deprivation of breast milk require consideration 
and study to comprehensively understand HEU infant risk for 
infectious morbidity (33, 34, 41, 71). In designing further stud-
ies and looking for possible interventions to secure HEU infant 
well-being, researchers need to be cognizant of the vulnerabilities 
that all infants and children experience, whether HIV exposed 
or not. Interventions that are found to improve health in HEU 
infants may very well also improve outcomes for HU infants. The 
bigger picture of improving health and well-being for all infants 
particularly in Africa needs to be kept in mind. HEU infants 
comprise almost one-third of the infant population in high bur-
den countries and their health and well-being, beyond avoiding 
HIV-infection, deserve a more prominent position in the local 
and international HIV research agendas.
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